Welcome to our dedicated news page for Ionis Pharmaceuticals (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ionis Pharmaceuticals 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ionis Pharmaceuticals 's position in the market.
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has appointed Michael Yang, an experienced biopharmaceutical executive, to its Board of Directors, expanding the total number of members to 10. Mr. Yang has over 20 years of leadership experience in biotech, pharmaceutical, and medical device companies, with significant achievements in launching new platforms, expanding global revenues, and diversifying product lines. His most recent role was as President, CEO, and Board member of ViaCyte, which was acquired by Vertex in 2022. Ionis' CEO, Brett P. Monia, and Board Chairman, Joseph Loscalzo, M.D., Ph.D., expressed excitement about Michael's appointment, highlighting his deep biopharmaceutical leadership experience and strong patient focus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
-
Rhea-AI Summary
IONIS: Part 1 of HALOS trial for ION582 in Angelman syndrome completes enrollment with positive preliminary findings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
IONIS Pharmaceuticals, Inc. (Nasdaq: IONS) announced positive results from a Phase 2 study of donidalorsen, showing a sustained 96% reduction in hereditary angioedema attacks over two years. Patients reported improved quality of life. Phase 3 results are expected in H1 2024. The drug received orphan drug designation in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals, Inc. will participate in fireside chats at several investor conferences in November and December 2023. The conferences include Guggenheim 5th Annual Inflammation, Neurology, & Immunology Conference, Stifel 2023 Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference 2023, and BMO 2023 Growth & ESG Conference. The presentations will be webcasted live on the Ionis website and replays will be available within 48 hours.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.91%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals reported positive Phase 3 data for Olezarsen, showing significant triglyceride lowering and reductions in acute pancreatitis attacks. Eplontersen is on track for regulatory approval in the EU and Canada, with potential approval in the US in December 2023. Ionis expects to achieve its 2023 financial guidance. Revenue for Q3 2023 was $144 million, a 10% decrease compared to the same period last year. Operating expenses increased due to investments in eplontersen, olezarsen, and donidalorsen. Ionis has $2.2 billion in cash and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
-
Rhea-AI Summary
Ionis Pharmaceuticals to host webcast to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals plans to bring new neurology medicines to its clinical pipeline by the end of 2024, positioning the company for significant revenue growth and positive cash flow. Last week, Ionis announced positive Phase 3 results for olezarsen in familial chylomicronemia syndrome, paving the way for independent commercial launches. Ionis also highlighted progress in its commercial and medical affairs organizations and the advancement of its neurology pipeline. The company has a strong financial foundation with $2B in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
-
Rhea-AI Summary
Publication of NEURO-TTRansform study shows eplontersen halted disease progression and improved quality of life in patients with ATTRv-PN. Eplontersen achieved an 82% reduction in TTR serum concentration compared to placebo group. It also demonstrated significant benefits on neuropathy impairment and quality of life. FDA action date in December. Ionis and AstraZeneca seeking regulatory approval globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
-
Rhea-AI Summary
Roche gains exclusive worldwide rights to develop, manufacture and commercialize investigational medicines for Alzheimer's disease and Huntington's disease discovered by Ionis. Ionis to receive $60 million upfront payment. Collaboration aims to accelerate the discovery and development of novel therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
Rhea-AI Summary
Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in FCS patients, with a statistically significant reduction in triglyceride levels and a 100% reduction in acute pancreatitis events. Plans to file a New Drug Application with the FDA. Favorable safety profile. Potential to become new standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
Ionis Pharmaceuticals, Inc.
Nasdaq:IONS
IONS Rankings
IONS Stock Data
6.27B
144.53M
0.86%
100.99%
6.53%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
CARLSBAD
About IONS
ionis pharmaceuticals, inc., located in the north san diego county city of carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. we are the pioneer in the discovery and development of antisense drugs with more than 1300 patents. ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. we are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. join us and experience our unique culture while you develop and expand your career. for more information about ionis and to apply for an open position, please visit our website: www.ionispharma.com.